$53.07 -0.41 (%) AbbVie Inc - NYSE

Feb. 10, 2016 | 02:55 PM

Partner Headlines

  1. The Generic Drug Battle

    Benzinga | Feb. 10, 2016 | 09:13AM EST
  2. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

    Benzinga | Feb. 8, 2016 | 15:27PM EST
  3. Benzinga's Top Initiations

    Benzinga | Feb. 5, 2016 | 09:32AM EST
  4. Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

    Benzinga | Feb. 3, 2016 | 13:16PM EST
  5. Earnings Recap For January 29

    Benzinga | Jan. 29, 2016 | 17:36PM EST
  6. Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

    Benzinga | Jan. 29, 2016 | 09:29AM EST
  7. AbbVie Falling After Q4 Report, 2016 Guidance Affirmation

    Benzinga | Jan. 29, 2016 | 08:14AM EST
  8. Earnings Scheduled For January 29, 2016

    Benzinga | Jan. 29, 2016 | 04:05AM EST
  9. Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA

    Benzinga | Jan. 28, 2016 | 04:29AM EST
  10. US Big Pharma: What To Watch For In Q4 Results

    Benzinga | Jan. 25, 2016 | 11:16AM EST
  11. Barron's 2016 Roundtable Part 2: Lots Of Savvy Investment Ideas

    Benzinga | Jan. 24, 2016 | 17:05PM EST
  12. Halozyme Confirms $5 Million Milestone Payment From AbbVie

    Benzinga | Jan. 21, 2016 | 14:54PM EST
  13. Alphabet, Apple In Tech Health Care 'Convergence'

    IBD | Jan. 21, 2016 | 08:02AM EST
  14. 11 Different Ways To Play The Bear Market (From 11 Traders)

    Benzinga | Jan. 14, 2016 | 14:38PM EST
  15. Lee Ainslie Gains From Liberty Global But Loses From Axiall

    GuruFocus | Jan. 13, 2016 | 12:01PM EST
  16. Roche

    IBD | Jan. 12, 2016 | 18:41PM EST
  17. AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

    Benzinga | Jan. 11, 2016 | 07:02AM EST
  18. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD | Jan. 8, 2016 | 15:34PM EST
  19. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  20. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD | Dec. 30, 2015 | 14:16PM EST
  21. 10 Undervalued Dividend Champions for 2016: Be Greedy When Others Are Fearful

    GuruFocus | Dec. 24, 2015 | 16:37PM EST
  22. Express Scripts Gets Mixed Reviews After '16 Guidance

    IBD | Dec. 22, 2015 | 12:41PM EST
  23. Gilead Buys Into Galapagos Drug That AbbVie Ditched

    IBD | Dec. 17, 2015 | 14:01PM EST
  24. Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds

    Benzinga | Dec. 12, 2015 | 14:05PM EST
  25. Benzinga's Top Upgrades

    Benzinga | Dec. 7, 2015 | 08:59AM EST
  26. IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients

    Benzinga | Dec. 7, 2015 | 08:31AM EST
  27. AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia

    Benzinga | Dec. 6, 2015 | 19:15PM EST
  28. AbbVie Announces Ibrutinib Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma

    Benzinga | Dec. 6, 2015 | 18:58PM EST
  29. AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion, Achived Primary Endpoint With 79.4% ORR

    Benzinga | Dec. 6, 2015 | 11:10AM EST
  30. Weekend Watch: Yahoo's Fate, Blood Cancer Fighters

    IBD | Dec. 5, 2015 | 08:02AM EST
  31. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  32. Merger Landscape Still Inviting To Inversions

    Benzinga | Dec. 2, 2015 | 20:18PM EST
  33. Blood-Cancer Fighters To Strut Their Stuff At ASH

    IBD | Dec. 2, 2015 | 08:02AM EST
  34. Gilead's HCV Pricing Policy Slammed By Senate Report

    IBD | Dec. 1, 2015 | 16:11PM EST
  35. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD | Dec. 1, 2015 | 15:31PM EST
  36. Barclays' Biopharmaceuticals Blueprint For 2016

    Benzinga | Dec. 1, 2015 | 11:54AM EST
  37. Morning Market Losers

    Benzinga | Dec. 1, 2015 | 09:52AM EST
  38. Benzinga's Top Downgrades

    Benzinga | Dec. 1, 2015 | 09:32AM EST
  39. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 1, 2015 | 08:24AM EST
  40. Are Buybacks At Apple, Nike, Other Firms Good Or Bad?

    IBD | Nov. 24, 2015 | 08:02AM EST
  41. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD | Nov. 23, 2015 | 16:06PM EST
  42. Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Health Care Providers

    GuruFocus | Nov. 20, 2015 | 18:26PM EST
  43. Health Care Investor Larry Robbins Sells Drug Manufacturers, Buys Providers

    GuruFocus | Nov. 20, 2015 | 18:26PM EST
  44. Pfizer-Allergan A Go Despite New Tax Inversion Rules?

    IBD | Nov. 19, 2015 | 19:05PM EST
  45. Pfizer, Allergan Near Deal Despite Treasury Warning

    IBD | Nov. 19, 2015 | 11:28AM EST
  46. Pfizer, Allergan Near Deal As Tax Inversion Rules Loom

    IBD | Nov. 18, 2015 | 22:38PM EST
  47. Gilead still tops in HCV drugs

    IBD | Nov. 18, 2015 | 18:48PM EST
  48. Treasury Plans New 'Targeted' Tax-Inversion Crackdown

    IBD | Nov. 18, 2015 | 18:05PM EST
  49. Gilead Seen Staying Top Dog In HCV, But Merck Rising

    IBD | Nov. 18, 2015 | 12:10PM EST
  50. AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C

    Benzinga | Nov. 16, 2015 | 09:03AM EST
Trading Center